Application of a multianalyte proteomic assay to document risk of future cardiovascular events in patients with type 2 diabetes

被引：0
|
作者：
Rantanen, Jouni [1 ]
Kazerooni, Rashid [1 ]
Kennedy, Caleb [1 ]
Shah, Svati [2 ]
Sourij, Harald [3 ]
Jonasson, Christian [4 ]
Hveem, Kristian [4 ]
Chadwick, Jessica [1 ]
Hinterberg, Michael [1 ]
Deo, Rajat [5 ]
Dubin, Ruth [6 ]
Ganz, Peter [7 ]
Williams, Steve [1 ]
机构：
[1] Somalogic, Boulder, CO USA
[2] Duke Univ, Sch Med, Durham, NC USA
[3] Med Univ Graz, Graz, Austria
[4] Norwegian Univ Sci & Technol, Trondheim, Norway
[5] Univ Penn, Philadelphia, PA 19104 USA
[6] Univ Texas Southwestern, Dallas, TX USA
[7] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY | 2023年 / 132卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
NORPM-O4
引用
收藏
页码：24 / 25
页数：2
相关论文
共 50 条
  • [21] Blood adiponectin levels are not associated with risk of cardiovascular events in patients with type 2 diabetes
    Jeon, Ja Young
    Ha, Kyoung Hwa
    Han, Seung Jin
    Kim, Hae Jin
    Lee, Kwan-Woo
    Kim, Dae Jung
    DIABETES & VASCULAR DISEASE RESEARCH, 2018, 15 (06): : 571 - 575
  • [22] Risk of major cardiovascular events in patients with type 2 diabetes with and without prior cardiovascular events: results from the LEADER trial
    Poulter, N. R.
    Bain, S. C.
    Buse, J. B.
    Monk-Hansen, T.
    Nauck, M.
    Rasmussen, S.
    Pratley, R.
    Zinman, B.
    Orsted, D.
    Marso, S. P.
    EUROPEAN HEART JOURNAL, 2017, 38 : 819 - 819
  • [23] Atorvastatin reduces cardiovascular events in patients with type 2 diabetes
    不详
    DIABETES OBESITY & METABOLISM, 2003, 5 (06): : 472 - 472
  • [24] Risk of Cardiovascular Events in Patients With Type 2 Diabetes and Metabolic Dyslipidemia Without Prevalent Atherosclerotic Cardiovascular Disease
    Rana, Jamal S.
    Liu, Jennifer Y.
    Moffet, Howard H.
    Sanchez, Robert J.
    Khan, Irfan
    Karter, Andrew J.
    AMERICAN JOURNAL OF MEDICINE, 2020, 133 (02): : 200 - 206
  • [25] No Increased Risk of Cardiovascular Events with Dapagliflozin in Elderly Patients with Type 2 Diabetes Mellitus, Cardiovascular Disease, and Hypertension
    Gause-Nilsson, Ingrid Ami
    Sonesson, Christian
    Johansson, Peter A.
    Sugg, Jennifer E.
    Johnsson, Eva
    DIABETES, 2015, 64 : A4 - A4
  • [26] No increased risk of cardiovascular events with dapagliflozin in elderly patients with type 2 diabetes mellitus, cardiovascular disease and hypertension
    Gause-Nilsson, I.
    Sonesson, C.
    Johansson, P. A.
    Johnsson, E.
    DIABETOLOGIA, 2015, 58 : S362 - S363
  • [27] Thiazolidinediones were associated with higher risk of cardiovascular events in patients with type 2 diabetes and cirrhosis
    Yen, Fu-Shun
    Wei, James Cheng-Chung
    Chiu, Lu-Ting
    Hsu, Chih-Cheng
    Hou, Ming-Chih
    Hwu, Chii-Min
    LIVER INTERNATIONAL, 2021, 41 (01) : 110 - 122
  • [28] Low birthweight in patients with type 2 diabetes is associated with elevated risk of cardiovascular events and mortality
    Hansen, Aleksander L.
    Brons, Charlotte
    Engelhard, Leonie M.
    Andersen, Mette K.
    Hansen, Torben
    Nielsen, Jens S.
    Vestergaard, Peter
    Hojlund, Kurt
    Jessen, Niels
    Olsen, Michael H.
    Sorensen, Henrik T.
    Thomsen, Reimar W.
    Vaag, Allan
    DIABETOLOGIA, 2024, 67 (08) : 1616 - 1629
  • [29] Correlation between circulating lipoprotein(a) levels and cardiovascular events risk in patients with type 2 diabetes
    Gu, Jun-Xu
    Huang, Juan
    Wang, Kun
    Yin, Yue
    Fang, Jun-Ling
    Zhang, Ai-Min
    Li, Shan-Shan
    Yao, Xiao-Qin
    Yang, Ming
    Zhang, Na
    Jia, Mei
    Su, Ming
    HELIYON, 2024, 10 (17)
  • [30] Increased risk of cardiovascular events as a result of delay in treatment intensification for patients with Type 2 diabetes
    Khunti, K.
    Paul, S.
    Thorsted, B. L.
    Wolden, M. L.
    Klein, K.
    DIABETIC MEDICINE, 2015, 32 : 116 - 116
12345